Lipaglyn™ (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
Akero to expand ongoing Phase IIa trial of AKR-001 for NASH
Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn™ (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Applied Therapeutics reports positive results from Galactosemia study
Applied Therapeutics has reported positive results from a Phase II portion of ACTION-Galactosemia study of AT-007 in adult Galactosemia patients.
Boehringer Ingelheim ends BI 1467335 development for NASH
Boehringer Ingelheim has discontinued BI 1467335 development for non-alcoholic steatohepatitis (NASH) treatment after reviewing results from a Phase I clinical trial.
Alnylam’s late-stage trial of lumasiran in PH1 meets endpoints
Alnylam Pharmaceuticals Phase III ILLUMINATE-A clinical trial of lumasiran has met the primary and secondary endpoints in patients suffering from primary hyperoxaluria type 1 (PH1).
Gilead combination therapy for NASH misses Phase II primary goal
Top-line data reported by Gilead Sciences has revealed that the Phase II ATLAS clinical trial of cilofexor, firsocostat and selonsertib did not meet the primary endpoint in nonalcoholic steatohepatitis (NASH) patients with bridging fibrosis (F3) and compensated cirrhosis (F4).
Arecor’s ultra-rapid acting insulin shows promise in Phase I trial
UK-based biopharmaceutical firm Arecor has announced that its ultra-rapid acting insulin candidate, AT247, demonstrated encouraging pharmacokinetic and pharmacodynamic profiles in a Phase I clinical trial.
Rexgenero opens enrolment for SALAMANDER trials in UK
Rexgenero has opened the first site in the UK to enrol diabetic patients with chronic limb-threatening ischemia (CLI) for the Phase III SALAMANDER studies of REX-001.
Ardelyx reports positive data from tenapanor’s Phase III CKD trial
Ardelyx has reported positive top-line data from Phase III PHREEDOM clinical trial of tenapanor to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Ionis and Akcea launch Phase III trial to treat polyneuropathy
Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have launched a Phase III clinical trial of AKCEA-TTR-L to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis.